GlaxoSmithKline R&D Under Scrutiny In Bid For Fresh Funding
Executive Summary
It's crunch time for GlaxoSmithKline PLC's 38 biotech-like R&D units, which are competing for further funding as they reach the end of their first three-year investment cycle.